Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.42 |
| ▸ | WNT3A | P56704 | 3/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | PPIA | P62937 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.39 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL958662 | 0.84 | LMNA (0.51) | LMNAGAACTNNB1WNT3ACNR2 | |
| SCHEMBL28839956 | 0.81 | ALDH1A1 (0.40) | SMN1; SMN2 | |
| SCHEMBL29770965 | 0.81 | ALDH1A1 (0.40) | SMN1; SMN2 | |
| SCHEMBL5558220 | 0.78 | LMNA (0.56) | LMNAGAACTNNB1WNT3ACNR2 | |
| SCHEMBL3915938 | 0.78 | NPC1 (0.46) | LMNAGAA | |
| SCHEMBL5825234 | 0.77 | CES2 (0.52) | LMNAGAASMN1; SMN2 | |
| SCHEMBL17950539 | 0.76 | KCNK3 (0.43) | GAAKCNK3KCNK9 | |
| SCHEMBL28634751 | 0.73 | LMNA (0.64) | LMNAGAACTNNB1WNT3ACNR2 | |
| SCHEMBL746794 | 0.73 | LMNA (0.64) | LMNAGAACTNNB1WNT3ACNR2 | |
| SCHEMBL3048180 | 0.73 | CES2 (0.52) | GAASMN1; SMN2NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107567439-A | The ketone derivatives of 2 homopiperazine, 1 base 4H, 1,3 benzothiazines 4 and the method for preparing the keto hydrochloride of 2 1,3 benzothiazine of (height) piperazine 4 | 洛桑联邦理工学院 | 2018-01-09 | — | — | CN | claimed |
| WO-2011075525-A1 | PROCESS FOR PREPARING CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | WO | disclosed |
| US-7135466-B2 | Quinoline and quinazoline derivatives and drugs containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-11-14 | — | — | US | disclosed |
| US-20060211717-A1 | Quinoline and quinazoline derivatives and drugs containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-09-21 | — | — | US | disclosed |
| US-20040132727-A1 | Quinoline and quinazoline derivatives and drugs containing the same | KIRIN HOLDINGS KABUSHIKI KAISHA (JP) | 2004-07-08 | — | — | US | disclosed |
| EP-1243582-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES AND DRUGS CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2002-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211717-A1 | Quinoline and quinazoline derivatives and drugs containing the same | PDGFRA, PDGFRB, PDGFA | LMNA 1836/4885GAA 2782/4885CTNNB1 3801/4885 |
| US-20040132727-A1 | Quinoline and quinazoline derivatives and drugs containing the same | PDGFRA, PDGFRB, PDGFA | LMNA 2078/4885GAA 2453/4885CTNNB1 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.